Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRL-17822 first-in-human ascending-dose and food-effect study in healthy men
NL-OMON33454Phase 1Active, not recruiting
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DRL-17822 in atherosclerosis and coronary arteriosclerosis (3 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoints: Safety and tolerability of ascending single doses, Food effect on pharmacokinetics and 1 more. Started Apr 2009; status: active, not recruiting.
02
Drugs
DRL-17822
03
Conditions
atherosclerosiscoronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON33454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33454.